Literature DB >> 32219844

Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation.

Hua Miao1, Gang Cao2, Xia-Qing Wu1, Yuan-Yuan Chen1, Dan-Qian Chen1, Lin Chen1, Nosratola D Vaziri3, Ya-Long Feng1, Wei Su4, Yi Gao5, Shougang Zhuang6, Xiao-Yong Yu7, Li Zhang8, Yan Guo9, Ying-Yong Zhao1.   

Abstract

BACKGROUND AND
PURPOSE: Increasing evidence has indicated that the high risk of cardiovascular disease in chronic kidney disease (CKD) patients cannot be sufficiently explained by classic risk factors. EXPERIMENTAL APPROACH: Based on the least absolute shrinkage and selection operator method, we identified significantly altered renal tissue metabolites during progressive CKD in a 5/6 nephrectomized rat model and in CKD patients. KEY
RESULTS: Six aryl-containing metabolites (ACMs) were significantly increased from Week 1 to Week 20. They were associated with the activation of aryl hydrocarbon receptor (AhR) and its target genes including CYP1A1, CYP1A2 and CYP1B1, which were further validated by molecular docking. Our study further demonstrated that AhR signalling could be activated by ACM in patients with idiopathic membranous nephropathy, diabetic nephropathy and IgA nephropathy. Most importantly, 1-aminopyrene (AP) showed strong positive and negative correlation with serum creatinine and creatinine clearance, respectively. AP significantly up-regulated the mRNA expressions of AhR and its three target genes in both mice and NRK-52E cells, while this effect was partially weakened in AhR small hairpin RNA-treated mice and NRK-52E cells. Furthermore, dietary flavonoid supplementation ameliorated CKD and renal fibrosis through partially inhibiting the AhR activity via lowering the ACM levels. The antagonistic effect of flavonoids on AhR was deeply influenced by the number and location of hydroxyl and glycosyl groups. CONCLUSION AND IMPLICATIONS: We uncovered that endogenous AP is a novel mediator of CKD progression via AhR activation; thus, AhR might serve as a promising target for CKD treatment.
© 2020 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32219844      PMCID: PMC7348091          DOI: 10.1111/bph.15062

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  64 in total

1.  Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust.

Authors:  N Hatanaka; H Yamazaki; R Kizu; K Hayakawa; Y Aoki; M Iwanari; M Nakajima; T Yokoi
Journal:  Carcinogenesis       Date:  2001-12       Impact factor: 4.944

2.  CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands.

Authors:  Bruno Lamas; Mathias L Richard; Valentin Leducq; Hang-Phuong Pham; Marie-Laure Michel; Gregory Da Costa; Chantal Bridonneau; Sarah Jegou; Thomas W Hoffmann; Jane M Natividad; Loic Brot; Soraya Taleb; Aurélie Couturier-Maillard; Isabelle Nion-Larmurier; Fatiha Merabtene; Philippe Seksik; Anne Bourrier; Jacques Cosnes; Bernhard Ryffel; Laurent Beaugerie; Jean-Marie Launay; Philippe Langella; Ramnik J Xavier; Harry Sokol
Journal:  Nat Med       Date:  2016-05-09       Impact factor: 53.440

3.  Lack of the aryl hydrocarbon receptor accelerates aging in mice.

Authors:  Isabel Bravo-Ferrer; María I Cuartero; Violeta Medina; Dalia Ahedo-Quero; Carolina Peña-Martínez; Alberto Pérez-Ruíz; M Encarnación Fernández-Valle; Catalina Hernández-Sánchez; Pedro M Fernández-Salguero; Ignacio Lizasoain; María A Moro
Journal:  FASEB J       Date:  2019-09-04       Impact factor: 5.191

4.  Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

Authors:  H Y Choi; J E Lim; J H Hong
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-03       Impact factor: 5.554

5.  Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

Authors:  Michael J Curtis; Steve Alexander; Giuseppe Cirino; James R Docherty; Christopher H George; Mark A Giembycz; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Yong Ji; David J MacEwan; Christopher G Sobey; S Clare Stanford; Mauro M Teixeira; Sue Wonnacott; Amrita Ahluwalia
Journal:  Br J Pharmacol       Date:  2018-04       Impact factor: 8.739

Review 6.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Authors:  Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

7.  Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease.

Authors:  Ya-Long Feng; Gang Cao; Dan-Qian Chen; Nosratola D Vaziri; Lin Chen; Jun Zhang; Ming Wang; Yan Guo; Ying-Yong Zhao
Journal:  Cell Mol Life Sci       Date:  2019-05-30       Impact factor: 9.261

8.  The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.

Authors:  Jennifer C Schroeder; Brett C Dinatale; Iain A Murray; Colin A Flaveny; Qiang Liu; Elizabeth M Laurenzana; Jyh Ming Lin; Stephen C Strom; Curtis J Omiecinski; Shantu Amin; Gary H Perdew
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

9.  Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands.

Authors:  William H Bisson; Daniel C Koch; Edmond F O'Donnell; Sammy M Khalil; Nancy I Kerkvliet; Robert L Tanguay; Ruben Abagyan; Siva Kumar Kolluri
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

10.  A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.

Authors:  Huiping Li; Jiang Liu; Jianing Chen; Huiyun Wang; Linbin Yang; Fei Chen; Siting Fan; Jing Wang; Bin Shao; Dong Yin; Musheng Zeng; Mengfeng Li; Jun Li; Fengxi Su; Qiang Liu; Herui Yao; Shicheng Su; Erwei Song
Journal:  Nat Commun       Date:  2018-04-24       Impact factor: 14.919

View more
  21 in total

1.  Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice.

Authors:  Gang Cao; Hua Miao; Yan-Ni Wang; Dan-Qian Chen; Xia-Qing Wu; Lin Chen; Yan Guo; Liang Zou; Nosratola D Vaziri; Ping Li; Ying-Yong Zhao
Journal:  Acta Pharmacol Sin       Date:  2022-05-16       Impact factor: 6.150

2.  Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease.

Authors:  Yan-Ni Wang; Zhi-Hao Zhang; Hong-Jiao Liu; Zhi-Yuan Guo; Liang Zou; Ya-Mei Zhang; Ying-Yong Zhao
Journal:  Acta Pharmacol Sin       Date:  2022-08-03       Impact factor: 7.169

3.  Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.

Authors:  Yan-Ni Wang; Hao-Yu Feng; Xin Nie; Ya-Mei Zhang; Liang Zou; Xia Li; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

4.  Aminoacylase-1 plays a key role in myocardial fibrosis and the therapeutic effects of 20(S)-ginsenoside Rg3 in mouse heart failure.

Authors:  Qiong Lai; Fu-Ming Liu; Wang-Lin Rao; Guang-Ying Yuan; Zhao-Yang Fan; Lu Zhang; Fei Fu; Jun-Ping Kou; Bo-Yang Yu; Fang Li
Journal:  Acta Pharmacol Sin       Date:  2021-12-16       Impact factor: 7.169

Review 5.  Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation.

Authors:  Jing-Ru Liu; Hua Miao; De-Qiang Deng; Nosratola D Vaziri; Ping Li; Ying-Yong Zhao
Journal:  Cell Mol Life Sci       Date:  2020-09-23       Impact factor: 9.261

6.  Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation.

Authors:  Hua Miao; Gang Cao; Xia-Qing Wu; Yuan-Yuan Chen; Dan-Qian Chen; Lin Chen; Nosratola D Vaziri; Ya-Long Feng; Wei Su; Yi Gao; Shougang Zhuang; Xiao-Yong Yu; Li Zhang; Yan Guo; Ying-Yong Zhao
Journal:  Br J Pharmacol       Date:  2020-05-28       Impact factor: 8.739

Review 7.  How Does Herbal Medicine Treat Idiopathic Membranous Nephropathy?

Authors:  Zhendong Feng; Wenbin Liu; Han Xue Jiang; Haoran Dai; Chang Gao; Zhaocheng Dong; Yu Gao; Fei Liu; Zihan Zhang; Qihan Zhao; Lei Zhang; Baoli Liu
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

Review 8.  Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System.

Authors:  Carlos Alexandre Falconi; Carolina Victoria da Cruz Junho; Fernanda Fogaça-Ruiz; Imara Caridad Stable Vernier; Regiane Stafim da Cunha; Andréa Emilia Marques Stinghen; Marcela Sorelli Carneiro-Ramos
Journal:  Front Physiol       Date:  2021-05-14       Impact factor: 4.566

Review 9.  Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease.

Authors:  Zhonghong Yan; Guanran Wang; Xingyang Shi
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

10.  Activation of aryl hydrocarbon receptor by 6-formylindolo[3,2-b]carbazole alleviated acute kidney injury by repressing inflammation and apoptosis.

Authors:  Sibei Tao; Fan Guo; Qian Ren; Jing Liu; Tiantian Wei; Lingzhi Li; Liang Ma; Ping Fu
Journal:  J Cell Mol Med       Date:  2020-12-06       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.